Search Within

Efrat Luttwak

Formats
  1. Meeting Abstract (16)
  2. Journal Article (6)
  3. Research Letter (2)
  4. Editorial (1)
  5. Review (1)
Groups
  1. GME, Medicine (26)
  2. Graduate Medical Education (26)
  3. Center for Hematologic Malignancies (24)
  4. Department of Medicine (24)
  5. Hematologic Malignancies, Division of (24)
  6. Lymphoma (24)

More Groups

People
  1. Maria Palomba (20)
  2. Gilles Salles (18)
  3. Magdalena Corona De Lapuerta (13)
  4. Roni Shouval (13)
  5. Alejandro Luna De Abia (12)
  6. Gunjan Shah (12)

More People

Years
  1. 2025 (4)
  2. 2024 (8)
  3. 2023 (14)
Publications
  1. Blood (15)
  2. Blood Cancer Journal (2)
  3. Bone Marrow Transplantation (2)
  4. Blood Advances (1)
  5. Blood Cancer Discovery (1)
  6. Current Opinion in Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Nature Publishing Group (4)
  3. American Association for Cancer Research (1)
  4. Biomed Central Ltd (1)
  5. Ferrata Storti Foundation (1)
  6. Informa Healthcare (1)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II multicenter clinical trial assessing the safety and efficacy of ixazomib, pomalidomide and dexamethasone combination as second or third-line treatment for triple-class exposed patients with relapsed and refractory multiple myeloma (iPod-790 Trial)
    Meeting Abstract

    Cohen, Y. C.; Shragai, T.; Lavi, N.; Vaxman, I.; Chubar, E.; Gatt, M. E.; Ganzel, C.; Magen, H.; Luttwak, E.; Mittelman, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • 18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma
    Meeting Abstract

    Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry
    Research Letter

    Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
    Editorial

    Luttwak, E.; Smith, M. R.; Zelenetz, A. D.
    Expert Opinion on Pharmacotherapy (2023)

    Fulltext@MSK | Save